Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).SAN MATEO, Calif., Sept. 5, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in the H.C. Wainwright 26th Annual Global Investment Conference and will be taking 1x1 meetings.
加州聖馬特奧，2024年9月5日 /環球新聞社/ - Talphera公司(Nasdaq: TLPH)（"Talphera"）是一家專注於開發和商業化創新治療方案，用於醫療監督環境中的特殊藥品公司，今天宣佈管理層將參加H.C. Wainwright第26屆全球投資大會，並將進行1x1會議。
The conference is being held on September 9-11, 2024, at the Lotte New York Palace Hotel in New York City, and the presentation will be available on-demand starting on Monday, September 9 at 7:00 AM ET here or by visiting the Investors section of the Company's website at and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section.
該大會將於2024年9月9日至11日在紐約市Lotte New York Palace酒店舉行，演示將於9月9日上午7:00在此處按需提供，或者通過訪問公司網站的投資者部分，點擊投資者/新聞與事件/即將舉行的活動中發佈的網絡廣播鏈接。
About Talphera, Inc.
關於Talphera公司
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).
Talphera公司是一家專注於開發和商業化創新治療方案，用於醫療監督環境中的特殊藥品公司。Talphera的主力產品Niyad是一種凝固酶的凍乾製劑，目前正在作爲體外循環抗凝劑進行調查設備豁免(IDE)研究，並已獲得美國食品和藥物管理局(FDA)的突破性設備認定地位。
This release is intended for investors only. For additional information about Talphera, please visit .
此公告僅針對投資者。有關Talphera的其他信息，請訪問。
SOURCE Talphera, Inc.
資訊來源：Talphera公司。
譯文內容由第三人軟體翻譯。
